CA-UC-DAVIS-HEALTH
A new UC Davis Eye Center study , in collaboration with France’s INSERM Stem Cell and Brain Research Institute , found that special patented glasses engineered with technically advanced spectral notch filters enhance color vision for those with the most common types of red-green color vision deficiency (“anomalous trichromacy”). Notably, the ability to identify and experience expanded color was also demonstrated when color blind test subjects were not wearing the glasses.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200713005065/en/
At least eight in 100 men (8%) and one in 200 women (0.5%) suffer from red-green color vision deficiency (CVD), totaling 13 million in the U.S. and 350 million worldwide. While those with normal color vision see in excess of one million hues and shades, the CVD see a vastly diminished range of colors. People with CVD experience colors as more muted and washed out, and some colors cause confusion or are more difficult to differentiate. With an undergraduate and graduate student body of nearly 40,000, UC Davis has an estimated 1,700 students with red-green CVD.
The study evaluated the impact of spectral notch filters on enhancing the chromatic responses of observers with red-green CVD over two weeks of usage. The filters (EnChroma glasses) are designed to increase the separation between color channels to help people with color blindness see colors more vibrantly, clearly and distinctly.
The research, published in Current Biology , had CVD participants wear the special filter glasses or placebo glasses. Over two weeks, they kept a diary and were re-tested on days 2, 4 and 11 but without wearing the glasses. The researchers found that wearing the filter glasses increased responses to chromatic contrast response in individuals with red-green color blindness. It is unclear how long the improvement lasts without wearing the filters, but the evidence shows that the effect persists for some time.
“Extended usage of these glasses boosts chromatic response in those with anomalous trichromacy (red-green color vision deficiency),” said John S. Werner , distinguished professor of ophthalmology and a leader in vision science at UC Davis Health. “We found that sustained use over two weeks not only led to increased chromatic contrast response, but, importantly, these improvements persisted when tested without the filters, thereby demonstrating an adaptive visual response.”
Werner noted that this effect cannot be achieved with broad-band filters sold as aids to the color blind. He and his research colleagues believe the study’s findings suggest that modifications of photoreceptor signals activate a plastic post-receptoral substrate in the brain that could potentially be exploited for visual rehabilitation.
“When I wear the glasses outside, all the colors are extremely vibrant and saturated, and I can look at trees and clearly tell that each tree has a slightly different shade of green compared to the rest," said Alex Zbylut, one of the color blind participants in the study who got the placebo glasses first and then tried the special filter version afterwards. "I had no idea how colorful the world is and feel these glasses can help color blind people better navigate color and appreciate the world."
Reactions from other participants about their experiences with the glasses can be found in the Supplement section of the Current Biology article.
Werner, lead author of the study, has published numerous scholarly works and was awarded the prestigious 2015 Verriest Medal from the International Colour Vision Society.
Co-authors on the study, Adaptive Changes in Color Vision from Long-Term Filter Usage in Anomalous but Not Normal Trichromacy , include Kenneth Knoblauch of the Université de Lyon and Inserm Stem Cell and Brain Research Institute in France, and Brennan Marsh-Armstrong, a medical student now at UC San Diego. The research was supported by the National Eye Institute and grants from LABEX CORTEX, Universite de Lyon, operated by the French National Research Agency.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200713005065/en/
Social Media:
https://www.facebook.com/UCDavisEyeCenter/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
